All In Biotech

NDA 019710 · Liebel-Flarsheim

Optiray 350

Ioversol · Injection · Radiographic Contrast Agent

Novel

Last checked: Nov 21, 2026Latest source record: Apr 25, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1988

Dec 30, 1988

Approved uses

7

Original approval plus efficacy supplements

Registered trials

9

1 Phase 3, 2 recruiting

FAERS reports

3,856

2,888 serious, 236 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS WITH INADVERTENT INTRATHECAL ADMINISTRATION FOR INTRA-ARTERIAL AND INTRAVENOUS USE ONLY Inadvertent intrathecal administration may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. [see Warnings and Precautions ( 5.1 )] WARNING: RISKS WITH INADVERTENT INTRATHECAL ADMINISTRATION FOR INTRA-ARTERIAL AND INTRAVENOUS USE ONLY Inadvertent intrathecal administration may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. ( 5.1 )

What it is approved for

From the label in effect Feb 17, 2023.

OPTIRAY is indicated for: OPTIRAY is a radiographic contrast agent indicated for the following: Intra-arterial Procedures ( 1.1 ) Adults: Cerebral Arteriography (300, 320 mg iodine/mL) Peripheral Arteriography (300, 320, 350 mg iodine/mL ) Visceral and Renal Arteriography, Aortography (320 mg iodine/mL) Coronary Arteriography and Left Ventriculography (320, 350 mg iodine/mL) Pediatric Patients: Angiocardiography (320, 350 mg iodine/mL) Intravenous Procedures ( 1.2 ) Adults: Computed tomography (CT) Imaging of Head and Body (300, 320, 350 mg iodine/mL) Venography (300, 320, 350 mg iodine/mL) Intravenous Excretory Urography (300, 320, 350 mg iodine/mL) Intravenous Digital Subtraction Angiography (350 mg iodine/mL) Pediatric Patients: CT Imaging of the Head and Body, and Intravenous Excretory Urography (320 mg iodine/mL) 1.1 Intra-arterial In adults OPTIRAY 300: cerebral arteriography and peripheral arteriography. OPTIRAY 320: cerebral arteriography, peripheral arteriography, visceral and renal arteriography, aortography, coronary arteriography, and left ventriculography. OPTIRAY 350: peripheral arteriography coronary arteriography, and left ventriculography. In pediatric patients OPTIRAY 320 and OPTIRAY 350: angiocardiography. 1.2 Intra-venous In adults OPTIRAY 300: CT imaging of the head and body, venography, and intravenous excretory urography. OPTIRAY 320: CT imaging of the head and body, venography, and intravenous excretory urography. OPTIRAY 350: CT imaging of the head and body, venography, intravenous excretory urography, and intravenous digital subtraction angiography (IV-DSA). In pediatric patients OPTIRAY 320: CT imaging of the head and body, and intravenous excretory urography.

Mechanism: Intravascular injection of ioversol opacifies vessels in the path of the flow of the contrast medium, permitting visualization of the internal structures until significant hemodilution occurs. In imaging of the body, iodinated contrast agents diffuse from the vascular into the extravascular space. In normal brain with an intact blood-brain barrier, contrast does not diffuse into the extravascular space. In patients with a disrupted blood-brain barrier, contrast agent accumulates in the interstitial space in the region of disruption.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 21, 1995 Supplement 18 · Efficacy
  • Jul 27, 1993 Supplement 17 · Efficacy
  • Mar 9, 1993 Supplement 16 · Efficacy
  • Dec 11, 1992 Supplement 12 · Efficacy
  • Jul 9, 1992 Supplement 7 · Efficacy
  • Jan 22, 1992 Supplement 4 · Efficacy
  • Dec 30, 1988 Original approval · Type 1 - New Molecular Entity
5 products under this application
  • OPTIRAY 350 · IOVERSOL 74% · INJECTABLE, INJECTION · Prescription
  • OPTIRAY 160 · IOVERSOL 34% · INJECTABLE, INJECTION · Discontinued
  • OPTIRAY 320 · IOVERSOL 68% · INJECTABLE, INJECTION · Prescription
  • OPTIRAY 300 · IOVERSOL 64% · INJECTABLE, INJECTION · Prescription
  • OPTIRAY 240 · IOVERSOL 51% · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Ioversol" as an intervention, any sponsor and status, largest first.

All 9 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • urticaria545
  • dyspnoea465
  • pruritus437
  • rash243
  • nausea217
  • throat irritation215
  • sneezing208
  • erythema206
  • nephropathy toxic200
  • cough193
  • anaphylactic shock176
  • vomiting172

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200466
200578
2006137
2007146
2008177
2009378
2010303
2011314
2012272
2013293
2014136
201588
2016136
2017170
2018151
2019159
2020129
2021153
2022118
202388
2024147
2025115
2026102

Recalls

1 FDA enforcement reports for this application.

  • Sep 13, 2019 · Class II · Terminated

    Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 80 on PubMed

Sponsor: Liebel-Flarsheim · Also marketed as Optiray 160, Optiray 320, Optiray 300, Optiray 240

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.